Home Medicine Company Completes Enrollment for Phase 2 Trial of “Immune Resetting” Peptide for...

Company Completes Enrollment for Phase 2 Trial of “Immune Resetting” Peptide for Allergic Diseases

35
0




Topline data expected in Q2 2023.



Continue reading…

Previous articleThe Patient Journey Tech Stack: Ten Pharma Predictions for 2023
Next articlePumpkin Minestrone Soup